Cardiac lipotoxicity is associated with structural remodeling and functional changes that are features of obesity-related cardiomyopathy. Both high fat diet and the ob/ob mutation lead to increased fatty acid (FA) uptake, elevated triacylglycerol (TAG) content, hypertrophy, and systolic and diastolic dysfunction in murine hearts. Cardiomyocyte-specific long-chain acyl-CoA synthetase 1 (ACSL1) deficiency (Acsl1 H-/-) results in a 90% reduction in FA activation, suggesting that Acsl1 ablation might alleviate obesity-associated myocardial dysfunction. Double knockout ob-Acsl1 H-/and ob-Acsl1 flox/flox control mice were treated with tamoxifen at 20 weeks of age; heart function, TAG content, and relevant gene expression were assessed immediately before and 2 and 5 weeks after treatment. Heart weights initially increased in lean and obese Acsl1 H-/mice, but normalized in ob-Acsl1 H-/mice by 5 weeks. Ventricular TAG content was decreased by 51% and 61% in ob-Acsl1 H-/mice 2 and 5 weeks after Acsl1 knockout induction, respectively.
Introduction
The adult healthy heart has a marked preference for oxidation of long-chain fatty acids (FA) to fuel its continuous contractile activity, but can readily switch to alternative energy substrates to preserve cardiac output under varying physiological conditions [1] . In contrast, pathologies such as metabolic syndrome, obesity and diabetes are characterized by a loss of cardiac metabolic flexibility as well as alterations in FA metabolism [1] [2] [3] that lead to excess cardiac lipid storage [2] [3] [4] [5] . Experimental and clinical studies have implicated myocardial lipid accumulation in the development of obesity-associated cardiomyopathies [1] ; however, the contribution of specific lipid species to disease pathogenesis has yet to be fully elucidated.
Whereas early studies linked increased TAG content to cardiac lipotoxicity, recent work has focused on the effect of diacylglycerol (DAG) and ceramide, which can sometimes (but not always) accompany increased intramyocardial TAG.
Excess cardiac TAG accumulation has been associated with altered lipid signaling, accumulation of reactive oxygen species, ER stress, and impaired mitochondrial function [1] .
Moreover, TAG-associated cardiac lipotoxicity in humans correlates with structural remodeling and functional changes that are features of obesity-related cardiomyopathy, such as left ventricular hypertrophy and impaired myocardial contractility [1] . For instance, impaired TAG lipolysis in a mouse model of Atgl deficiency results in severe cardiac lipid accumulation, cardiac dysfunction, and premature death, in part due to a defect in PPARα activation [6, 7] . In rodent models, both high fat diet [8, 9] and leptin deficiency [10, 11] result in increased cardiac FA uptake, elevated TAG content, cardiac hypertrophy, and systolic and diastolic dysfunction. Conversely, obesity-associated heart dysfunction is ameliorated by reducing cardiac FA uptake [12, 13] , and by increasing FA oxidation [14] , lipoprotein secretion [15] , or esterification of free FA [16] .
ACSLs catalyze the conversion of FA to acyl-CoAs, an obligatory step for their downstream use as either energy substrates in β-oxidation or as building blocks in the synthesis of TAG and other complex lipids. ACSL1 is the major cardiac ACSL isoform in a family of 5 closely-related isoenzymes, contributing 50-90% of the total ACS activity. Cardiomyocytespecific Acsl1 ablation (Acsl1 H-/-) leads to > 90% reduction in mitochondrial FA oxidation, a 35% decrease in lipid uptake, and an 8-fold increase in glucose uptake and use [17, 18] . Notably, Acsl1 knockout does not affect cardiac TAG levels, suggesting that ACSL1-mediated activation channels FA specifically towards oxidation in the heart. However, long-term ACSL1 inactivation is also accompanied by deleterious effects, including glucose intolerance, development of mTORC1-mediated pathological hypertrophy, and diastolic dysfunction [17, 18] . In contrast, partial (~60%) cardiac ACSL1 knockdown is sufficient to elicit cardiac-specific metabolic derangements and the development of hypertrophy without affecting cardiac function [19] . We therefore hypothesized that partial Acsl1 ablation could reverse ventricular TAG accumulation and ameliorate myocardial dysfunction in the ob/ob model of cardiomyopathy. Our findings suggest that preventing or reversing cardiac lipid accumulation in the context of established lipotoxicity contributes to improved cardiac function, revealing Acsl1 as a potential target in the development of cardiovascular therapies for obesity-associated cardiomyopathies.
Materials and Methods
Animal Treatment. The University of North Carolina Institutional Animal Care and Use Committee approved all protocols. Mice were housed in a pathogen-free barrier facility (12-h light/12-h dark cycle) with free access to water and food (Prolab RMH 3000 SP76 chow). Acsl1 H-/- [17] and ob/+ [20] mice were bred to generate an ob-Acsl1 H-/double knockout model ( Fig. 1A) . At 20 weeks of age, ob-Acsl1 H-/and lean and obese Acsl1 flox/flox littermate control mice were injected intraperitoneally with tamoxifen (3 mg/40 g of body weight) (Sigma) dissolved in corn oil (20 mg/ml) for 4 consecutive days; all mice were injected with tamoxifen to adequately control for both the intrinsic effects of Cre/tamoxifen [21] and the TAG species alterations that result from corn oil vehicle treatment.
Systolic and diastolic heart function was examined by M-mode echocardiography and mitral Doppler analysis immediately before, and 2 and 5 weeks after tamoxifen treatment. Two and five weeks after tamoxifen induction, animals were anesthetized with 2,2,2-tribromoethanol (Avertin) and tissues were removed and snap-frozen in liquid nitrogen ( Fig. 1B) . To isolate total membranes, left ventricles were homogenized with 10 up-and-down strokes using a motor-driven Teflon pestle and glass mortar in ice-cold medium I (MedI) buffer Echocardiography and Doppler Analysis. Cardiac echocardiography was performed (blinded to mouse type and treatment) on unanesthetized mice with the VisualSonics Vevo 770 or Vevo 2100 ultrasound biomicroscopy system as described [17, 18] . M-mode images of the left ventricle were analyzed using VisualSonics software. Doppler analysis of the mitral valve to determine the mitral inflow velocity was performed on lightly anesthetized mice (2% (vol/vol) isoflurane/100% oxygen) as described [18, 22] . mM ATP, and 0.25 mM coenzyme A (CoA) in total membrane fractions from ventricles (2-6 μg protein) as described [17] . No ACSL activity was measurable in the soluble (cytosolic) fraction. Histology. Heart ventricles were fixed for 24h in PBS containing 4% paraformaldehyde, transferred to 70% ethanol, embedded in paraffin, serial sectioned, and stained with Masson's trichrome. Slides were scanned using an Aperio ScanScope (Aperio Technologies); images of left ventricular myocardium were selected for figure 2F.
RT
Statistics. Values are expressed as mean ± standard error of the mean (SEM). Differences between genotypes were evaluated by two-tailed unpaired Student's t-test. Differences between lean and obese groups were evaluated by two-way ANOVA with Tukey multiple-comparison posttests. All statistical analyses were performed using GraphPad Prism (version 6.0). For all tests, p < 0.05 was considered significant.
Results

Acsl1 ablation does not exacerbate obesity-induced cardiac hypertrophy or fibrosis.
Disruption of leptin signaling has been linked to cardiac hypertrophy [5, 24, 25] . Total cardiacspecific Acsl1 ablation is achieved 10 weeks after tamoxifen treatment and results in >90% reduction in cardiac ACSL activity and FA oxidation, a compensatory shift towards glucose uptake and use, and the development of mTOR-responsive hypertrophy and diastolic dysfunction [17, 18] .
Conversely, partial deficiency of ACSL1-mediated FA activation observed 2 weeks after tamoxifen treatment induces changes in cardiac metabolism and size without affecting heart function [19] .
Thus, we set out to examine whether partial Acsl1 inactivation at both early (2 weeks) and intermediate (5 weeks) time points could ameliorate heart dysfunction in the context of obesityassociated cardiomyopathy. We induced cardiac-specific Acsl1 knockdown in 20-week old obese mice and in lean littermate controls, and examined hearts 2 and 5 weeks after tamoxifen treatment ( Fig. 2 ). ACSL1 protein and ACSL activity were still detected 2 weeks after Acsl1 inactivation, but these levels were drastically reduced at 5 weeks ( Fig. 2A ). Ventricular ACSL activity was reduced by ~60% 2 weeks after tamoxifen treatment, whereas <10% of normal activity was observed in hearts 5 weeks after knockout induction, similar to the total Acsl1 ablation that occurs 10 weeks after tamoxifen treatment [17, 18] . As observed in numerous earlier studies [4, 5, [24] [25] [26] , leptin deficiency was accompanied by left ventricular hypertrophy ( Fig. 2B , "Pre"), with left ventricle masses that were 25% greater in 20-wk old ob/ob mice compared to lean littermate controls. Acsl1 abrogation resulted in enlarged hearts in lean mice 2 and 5 weeks after tamoxifen treatment, but did not contribute to increased hypertrophy in obese mice. In addition, partial ACSL1 knockdown did not alter the expression of pathological hypertrophy markers ( Fig. 2C ) or mTOR targets ( Fig. 2D ), while mTOR-mediated phosphorylation of p70 S6 kinase (S6K) was dramatically upregulated in the context of obesity ( Fig. 2E ). As shown previously [34] , short-term inactivation of Acsl1 resulted in a transient increase in cardiac fibrosis in lean and obese mice 2 weeks after tamoxifen treatment, but did not exacerbate the mild fibrosis observed in hearts from obese mice ( Fig. 2F ).
Acsl1 inactivation reduces ventricular stores of TAG without altering systemic lipid
metabolism. The cardiac-specific knockdown of Acsl1 did not affect total body or relative tissue weight in ob/ob mice ( Fig. 3A ). Expression of cardiac FA transporters and de novo FA synthesis genes is elevated in ob/ob hearts [26] , and studies have suggested that increased levels of SREBP-1c and its targets, Gpat1 and Acc1, lead to elevated rates of hepatic FA and TAG synthesis [27] . However, in agreement with a previous study [5] , we did not observe differences in cardiac expression of SREBP-1c targets between ob/ob and lean controls ( Fig. 3B ). Moreover, cardiac expression of key genes involved in glucose metabolism and circulating levels of TAG ( Fig. 3C) were unaltered, suggesting that partial ablation of cardiac ACSL1 does not affect cardiac or systemic glucose homeostasis and FA synthesis. In contrast, ventricular TAG content was decreased by 51% and 61% in ob-Acsl1 H-/mice 2 and 5 weeks after Acsl1 inactivation, respectively ( Fig. 3D ), indicating that partial cardiac-specific Acsl1 abrogation is sufficient to reverse established cardiac lipid accumulation.
Acsl1 knockdown ameliorates obesity-induced systolic dysfunction and may be protective
in ob/ob hearts subjected to stress. We hypothesized that reversing TAG accumulation could ameliorate obesity-associated cardiomyopathy in ob/ob hearts. Ejection Fraction (EF), a measure of heart contractility, and Fractional Shortening (FS), a parameter of cardiac output, were analyzed by M-mode echocardiography in conscious mice before and 2 and 5 weeks after tamoxifen treatment ( Fig. 4A ). As expected, cardiac systolic function was decreased in 20-wk old ob/ob mice compared to littermate controls. Interestingly, Acsl1 knockdown resulted in a previously undescribed, transient decline in systolic function 2 weeks after tamoxifen treatment, and contributed slightly to decreased function in ob/ob hearts; however, normal systolic function was restored 5 weeks after tamoxifen injection, when cardiac ACSL1 activity was virtually absent and ventricular TAG stores were markedly diminished in obese hearts. Moreover, ob/ob hearts exhibited hallmarks of dilated cardiomyopathy and reduced contractility including increased LV diameter, LV volume, and stroke volume, all of which resolved 5 weeks after Acsl1 knockdown ( Table 2 ). We posit that the temporary dip in function resulted from an initial compensatory process during which cardiac efficiency is decreased through oxygen use for non-contractile purposes [19, 28] , and that it had not been previously observed due to differences in age and gender of the animals studied [17, 18, 29] . deficiency likely protects obese hearts that are subjected to stress. Given the observed variability in ventricular TAG levels in obese mice (Fig. 3D ), we hypothesize that the apparent normal diastolic function we observed in obese mice at weeks 2 and 5 was due to "selection" for those mice whose lower cardiac TAG content made them inherently more resilient to stress.
Discussion
The ability to readily switch between metabolic substrates confers on cardiac muscle the flexibility required to sustain cardiac output when faced with changes in substrate availability, hormonal status, or physiological conditions. Although the heart can metabolize glucose, lactate, and ketone bodies to produce energy, 60-90% of the cardiac energy requirement is met preferentially through the oxidation of long-chain FA [3, 6, 7, 30] . Cardiac metabolism is therefore tightly regulated in response to intracellular levels of FA: increased FA availability (and concomitant PPARα activation) lead to decreased use of glucose with elevated FA oxidation and esterification rates [31] . Under physiological increases in FA influx where cardiac oxidative capacity is saturated, TAG accumulation limits the availability of FA for incorporation into lipotoxic species. In contrast, in pathologies such as obesity and diabetes in which metabolic stress becomes chronic and metabolic flexibility is impaired, FA overload leads to a compensatory but insufficient increase in cardiac FA oxidation [2, 11] , ultimately resulting in maladaptive TAG accumulation that promotes cardiac dysfunction [2, 4, 5, 10] . Our work shows that Acsl1 knockdown elicits a dramatic reversal of established ventricular steatosis and the subsequent amelioration of accompanying cardiac dysfunction. Although both total and short-term Acsl1 inactivation result in increased LV mass [17, 18] , partial Acsl1 abrogation did not exacerbate the hypertrophy observed in obese hearts. Obese hearts exhibited only mild cardiac fibrosis, in agreement with the discordant findings of other studies [32, 33] , and partial ACSL1 deficiency was associated with a moderate and transient upregulation in fibrosis [19] in both lean and obese mice that disappeared 5 weeks after knockout induction. Finally, partial Acsl1 ablation drastically reduced ventricular TAG content, ameliorated cardiac dysfunction, and was protective in ob/ob hearts subjected to stress. Thus, the detrimental effects of chronic Acsl1 deficiency were circumvented, revealing Acsl1 modulation as a potential therapeutic strategy to mobilize intraventricular TAG in obesity-related cardiomyopathy.
That increased myocardial TAG depots correlate with LV hypertrophy, impaired diastolic function, and higher oxygen consumption has been established in the ob/ob model of obesityassociated cardiomyopathy [5, 11] . However, how excess myocardial lipid storage is associated with heart disease is less clear, and overproduction of reactive oxygen species, mitochondrial membrane potential dissipation, impaired Ca 2+ homeostasis, and the generation of lipotoxic and pro-apoptotic intermediates have all been postulated as likely culprits for obesity-associated heart failure [1, 10, [34] [35] [36] [37] . Moreover, recent studies have focused on DAG and ceramides as the main contributors to obesity-associated cardiac dysfunction, proposing that TAG accumulation is a relatively innocuous player. Studies in murine models of cardiac-specific overexpression of ACSL1 [34] and DGAT1 [16] suggest that cardiac lipotoxicity is driven primarily by ceramides and DAG. In addition, increased myocardial ceramide levels in the presence of decreased TAG levels have been implicated in failing human myocardium, and TAG accumulation is present in patients with and without cardiac dysfunction [38] [39] [40] [41] , whereas severe heart failure can lead to reduced TAG and increased ceramides and DAG [3] . Cardiac-specific DGAT1 overexpression is thought to reduce toxicity associated with other transgenic models by reducing ceramide content without altering TAG levels [1] . Similarly, the cardiomyopathy observed in cardiac-specific ACSL1 overexpression is postulated to arise from selective loss of lipid-laden cardiomyocytes via ceramide-induced apoptosis [34] . However, pharmacological inhibition of de novo ceramide synthesis alleviates hypertrophy but does not restore survival in a model of cardiac-specific overexpression of lipoprotein lipase [42] . In addition, FA-induced apoptosis is triggered by the generation of ROS independently of ceramide synthesis [43] , further suggesting that other mechanisms underlie cardiac pathologies associated with intramyocardial lipid accumulation.
Thus, whether TAG plays an independent role in the development of cardiac dysfunction remains to be determined. Hearts from ob/ob mice have elevated levels of ceramides compared to lean controls, whereas DAG content is not affected [44] . In our study, a 60% reduction in ventricular ACSL activity was sufficient to reverse ventricular TAG accumulation in ob/ob hearts. Ceramide synthesis requires ACSL1-mediated activation of palmitate. Thus, partial cardiac-specific ACSL1 deficiency led to the mobilization of endogenous TAG stores while simultaneously blocking the availability of the newly-released FA for oxidation and/or incorporation into lipotoxic and proapoptotic species. The hydrolysis of existing TAG stores in ob/ob hearts that occurs after Acsl1 inactivation would therefore increase cardiac DAG (which cannot be re-esterified due to the block in FA activation) in the context of already elevated ceramide levels, and should therefore further promote deterioration of cardiac function: yet function is improved. These findings suggest that TAG may indeed play a principal role in the development of obesity-associated cardiomyopathy.
Decreased calcium handling in db/db mice leads to reduced cardiac contractility [45] .
Palmitate exposure results in mitochondrial membrane potential dissipation, increased ROS production, and impaired calcium signaling exclusively in wild type cardiomyocytes compared to ob/ob hearts [37] , suggesting that prolonged exposure to excess FA can result in cardiomyocyte adaptation. Nonetheless, ob/ob mice exhibit decreased expression of sarco/endoplasmic reticulum Ca 2+ -ATPase and perturbed intracellular calcium homeostasis [4, 46] . Could obesityassociated cardiac insufficiency be therefore compounded by a physical hindrance resulting from massive intramyocardial TAG accumulation? Mitochondria-associated membranes (MAMs) are sites of calcium exchange and have been implicated in the pathogenesis of cardiac hypertrophy and dysfunction [47] . Moreover, obesity-mediated intracellular lipid accumulation can elicit MAM reorganization [48] , leading to tissue-specific effects. Thus, excessive ventricular TAG accumulation could lead to mechanical disruption of MAM interactions, or conversely, increased 13 ER-mitochondria contacts, ultimately resulting in calcium signaling disruption and reduced cardiac contractility. Based on our findings, we speculate that the independent role of TAG accumulation on obesity-associated cardiomyopathy has been understated, and warrants further investigation. 
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